Profile data is unavailable for this security.
About the company
Predictive Oncology Inc. is a knowledge-driven company focused on applying artificial intelligence (AI) to support the development of cancer therapies. The Company operates through three segments: Pittsburgh, Birmingham, and Eagan. Pittsburgh segment provides services, which include the application of artificial intelligence (AI) using its proprietary biobank of 150,000 plus tumor samples. Pittsburgh segment also develops tumor-specific in vitro models for oncology drug discovery and research. Birmingham segment focuses on contract services and research for biopharmaceutical company clients and academic collaborators, focused on solubility improvements, stability studies, and protein production. Specifically, Birmingham provides optimized formulations for vaccines, antibodies, and other protein therapeutics. Eagan segment produces the STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal.
- Revenue in USD (TTM)1.96m
- Net income in USD-14.78m
- Incorporated2013
- Employees34.00
- LocationPredictive Oncology Inc91 43RD STREET, SUITE 110PITTSBURGH 15201United StatesUSA
- Phone+1 (412) 432-1500
- Fax+1 (651) 379-5024
- Websitehttps://predictive-oncology.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ReShape Lifesciences Inc | 8.34m | -10.92m | 4.22m | 31.00 | -- | 0.9313 | -- | 0.5066 | -2.30 | -2.30 | 0.7319 | 0.1933 | 0.6781 | 0.8178 | 4.52 | 268,871.00 | -88.83 | -136.06 | -162.20 | -194.32 | 65.85 | 56.30 | -130.99 | -408.36 | 1.26 | -- | 0.00 | -- | -22.79 | -0.9474 | 75.36 | -- | -49.29 | -- |
| Pressure Biosciences Inc | 2.27m | -29.56m | 4.62m | 15.00 | -- | -- | -- | 2.03 | -1.70 | -1.70 | 0.1299 | -1.22 | 1.02 | 2.28 | 9.17 | 151,505.30 | -1,074.63 | -643.54 | -- | -- | 6.89 | 34.75 | -1,050.30 | -798.21 | 0.0185 | -0.4182 | -- | -- | -13.64 | -5.05 | 21.52 | -- | -34.47 | -- |
| Avinger Inc | 7.62m | -16.13m | 4.81m | 68.00 | -- | -- | -- | 0.6308 | -18.16 | -18.16 | 7.49 | -2.56 | 0.4084 | 1.20 | 6.38 | 112,102.90 | -102.83 | -70.93 | -- | -131.57 | 22.43 | 30.87 | -251.78 | -208.91 | 0.4764 | -10.02 | 1.38 | -- | -7.51 | -0.6736 | 32.76 | -- | -24.21 | -- |
| Vapotherm Inc | 70.07m | -54.94m | 5.35m | 182.00 | -- | -- | -- | 0.0763 | -8.62 | -8.62 | 11.00 | -11.02 | 0.8122 | 1.46 | 7.53 | 385,011.00 | -63.68 | -49.73 | -587.27 | -62.54 | 45.28 | 43.56 | -78.40 | -78.99 | 0.1259 | -1.27 | 2.59 | -- | 2.80 | 10.14 | 48.62 | -- | -10.38 | -- |
| ADM Tronics Unlimited Inc | 2.85m | -716.86k | 5.41m | 7.00 | -- | 4.90 | -- | 1.90 | -0.0106 | -0.0106 | 0.0421 | 0.0163 | 0.9772 | 3.85 | 4.25 | -- | -24.62 | -11.45 | -38.81 | -15.77 | 38.45 | 43.73 | -25.19 | -15.28 | 1.24 | -- | 0.2902 | -- | 14.66 | -0.4159 | 93.04 | -- | -- | -- |
| BIOLASE Inc | 49.16m | -37.62m | 5.49m | 157.00 | -- | -- | -- | 0.1117 | -37.97 | -37.97 | 38.54 | 0.5726 | 1.34 | 2.38 | 8.68 | 313,146.50 | -56.30 | -49.28 | -115.21 | -85.80 | 34.02 | 35.27 | -41.97 | -50.72 | 0.683 | -6.61 | 0.8778 | -- | 1.45 | 1.27 | -30.39 | -- | 18.63 | -- |
| Encision Inc | 6.87m | -448.00k | 5.88m | 31.00 | -- | 2.68 | -- | 0.8568 | -0.0381 | -0.0381 | 0.5835 | 0.1863 | 1.64 | 1.96 | 7.84 | 221,520.00 | -10.69 | -1.07 | -14.05 | -1.46 | 50.54 | 52.27 | -6.52 | -0.613 | 1.08 | -6.22 | 0.1123 | -- | -4.17 | -3.44 | -393.90 | -- | 12.89 | -- |
| Sonendo Inc | 40.19m | -57.74m | 6.00m | 216.00 | -- | 0.2444 | -- | 0.1492 | -0.6125 | -0.5552 | 0.426 | 0.3482 | 0.4448 | 2.07 | 7.58 | 186,055.60 | -63.91 | -- | -78.82 | -- | 27.64 | -- | -143.67 | -- | 2.14 | -10.83 | 0.4695 | -- | 5.30 | -- | -6.78 | -- | -- | -- |
| Fuse Medical Inc | 18.40m | 3.63m | 6.06m | 31.00 | 2.28 | -- | 1.64 | 0.3295 | 0.036 | 0.036 | 0.2307 | -0.0031 | 0.9593 | 0.7018 | 5.75 | 593,671.90 | 18.91 | 0.7504 | 48.45 | 1.35 | 64.95 | 54.98 | 19.72 | 0.6552 | 0.3143 | -1.13 | 1.12 | -- | -8.67 | -6.72 | 295.11 | 34.66 | -- | -- |
| Guided Therapeutics Inc | 82.00k | -3.23m | 6.07m | 4.00 | -- | -- | -- | 74.02 | -0.0623 | -0.0623 | 0.0016 | -0.0721 | 0.0374 | 0.0904 | 11.71 | 20,500.00 | -137.80 | -136.13 | -- | -- | 32.93 | 29.39 | -3,685.37 | -3,666.67 | 0.1138 | -11.13 | -- | -- | 653.85 | 11.45 | 24.40 | -- | -- | -- |
| Sigyn Therapeutics Inc | 0.00 | -3.56m | 6.43m | 5.00 | -- | -- | -- | -- | -3.04 | -3.04 | 0.00 | -3.28 | 0.00 | -- | -- | 0.00 | -724.37 | -493.15 | -- | -- | -- | -- | -- | -10,223.96 | 0.0199 | -1.92 | -- | -- | -- | -- | -41.51 | -- | -- | -- |
| Arch Therapeutics Inc | 130.55k | -8.43m | 6.62m | 8.00 | -- | -- | -- | 50.72 | -3.68 | -3.68 | 0.0425 | -2.45 | 0.0833 | 0.0637 | -- | 16,318.75 | -538.25 | -188.28 | -- | -804.63 | 33.37 | -- | -6,458.14 | -26,945.92 | 0.0164 | -1.27 | -- | -- | 383.83 | -- | -32.35 | -- | -21.76 | -- |
| Predictive Oncology Inc | 1.96m | -14.78m | 6.64m | 34.00 | -- | 1.62 | -- | 3.39 | -3.66 | -3.66 | 0.4853 | 0.9977 | 0.1099 | 1.71 | 4.95 | 57,642.65 | -82.89 | -91.80 | -108.54 | -126.29 | 64.18 | 64.64 | -754.19 | -1,419.99 | 1.35 | -- | 0.0093 | -- | 18.24 | 4.75 | 45.67 | -- | 5.44 | -- |
| Vivos Therapeutics Inc | 13.36m | -15.64m | 6.74m | 114.00 | -- | 9.81 | -- | 0.5048 | -11.00 | -11.00 | 8.73 | 0.2131 | 0.9247 | -- | 31.59 | 117,219.30 | -108.24 | -89.72 | -243.30 | -149.70 | 58.90 | 70.20 | -117.06 | -113.15 | -- | -- | 0.00 | -- | -13.87 | 29.48 | 43.04 | -- | -8.48 | -- |
| Neurometrix Inc | 5.27m | -7.98m | 7.74m | 26.00 | -- | 0.4079 | -- | 1.47 | -6.32 | -6.32 | 4.20 | 9.44 | 0.2381 | 1.25 | 10.08 | 202,700.40 | -36.07 | -23.24 | -38.94 | -27.26 | 61.97 | 59.17 | -151.51 | -48.88 | 10.11 | -- | 0.00 | -- | -28.52 | -18.18 | -47.84 | -- | 5.03 | -- |
| Nexalin Technology Inc | 158.86k | -4.94m | 7.88m | 6.00 | -- | 3.39 | -- | 49.62 | -0.6676 | -0.6676 | 0.0215 | 0.3129 | 0.0363 | 0.1778 | 44.01 | 26,476.67 | -112.76 | -- | -139.94 | -- | 82.54 | -- | -3,110.58 | -- | 4.75 | -- | 0.00 | -- | -91.62 | -- | -173.80 | -- | -- | -- |
Data as of May 24 2024. Currency figures normalised to Predictive Oncology Inc's reporting currency: US Dollar USD
8.56%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 142.09k | 3.50% |
| Raymond James & Associates, Inc. (Invt Mgmt)as of 31 Mar 2024 | 120.81k | 2.97% |
| Geode Capital Management LLCas of 31 Mar 2024 | 37.58k | 0.93% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 17.18k | 0.42% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 13.84k | 0.34% |
| Carnegie Mellon University (Investment Management)as of 31 Mar 2024 | 10.36k | 0.26% |
| Tower Research Capital LLCas of 31 Mar 2024 | 2.69k | 0.07% |
| Vanguard Global Advisers LLCas of 31 Mar 2024 | 1.43k | 0.04% |
| UBS Securities LLCas of 31 Mar 2024 | 1.26k | 0.03% |
| Osaic Wealth, Inc. (Investment Management)as of 31 Mar 2024 | 425.00 | 0.01% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
